Monte Rosa Therapeutics (GLUE) Receivables - Other (2022 - 2026)

Monte Rosa Therapeutics' Receivables - Other history runs 5 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 227.34% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (up 227.34% YoY), while the FY2025 annual figure was $4.6 million, up 1485.54% from the prior year.
• Receivables - Other for Q1 2026 stood at $4.6 million, up from -$365000.0 in the prior quarter.
• The five-year high for Receivables - Other was $5.0 million in Q3 2025, with the low at -$422000.0 in Q4 2024.
• The 5-year median for Receivables - Other is $842000.0 (2024), against an average of $1.5 million.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other jumped 3260.0% in 2023, then sank 225.6% in 2024.
• Monte Rosa Therapeutics' Receivables - Other stood at $10000.0 in 2022, then surged by 3260.0% to $336000.0 in 2023, then tumbled by 225.6% to -$422000.0 in 2024, then gained by 13.51% to -$365000.0 in 2025, then soared by 1362.74% to $4.6 million in 2026.
• Business Quant data shows GLUE's Receivables - Other at $4.6 million in Q1 2026, -$365000.0 in Q4 2025, and $5.0 million in Q3 2025.